发明名称 Use of calcitonin in osteoarthritis
摘要 The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
申请公布号 US8765675(B2) 申请公布日期 2014.07.01
申请号 US201012819583 申请日期 2010.06.21
申请人 Novartis AG 发明人 Azria Moise;Christiansen Claus;Bateman Simon David;Li Shoufeng
分类号 A61K38/23;A61P19/00;A61P19/02;A61P19/08;A61P19/10;C07K14/585 主分类号 A61K38/23
代理机构 Dilworth & Barrese, LLP 代理人 Pokalsky Ann R.;Dilworth & Barrese, LLP
主权项 1. A method of reducing cartilage degeneration and/or bone resorption in an osteoarthritis patient or in a post-menopausal woman, said method comprising orally administering to said patient or to said post-menopausal woman, a pharmaceutical composition comprising salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzyol]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof, wherein the amount of said salmon calcitonin in said pharmaceutical composition is between 0.4 and 1.2 mg.
地址 Basel CH